Research programme: RNA interference-based respiratory disorder therapeutics - Alnylam
Alternative Names: siRNA targeting IKK-beta - Alnylam; siRNA targeting IKK2 - AlnylamLatest Information Update: 14 May 2014
At a glance
- Originator Alnylam Pharmaceuticals
- Developer Alnylam Pharmaceuticals; Imperial College of Science, Technology and Medicine; Justus Liebig University
- Class Small interfering RNA
- Mechanism of Action I-kappa B kinase inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pulmonary fibrosis; Respiratory tract disorders
Most Recent Events
- 18 Oct 2013 Discontinued - Preclinical for Pulmonary fibrosis in Germany (Parenteral)
- 18 Oct 2013 Discontinued - Preclinical for Respiratory tract disorders in Germany (Parenteral)
- 06 May 2011 No development reported - Preclinical for Pulmonary fibrosis in Germany (Parenteral)